Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024)

Zevra Therapeutics (ZVRA) has disclosed Finished Goods for 2 consecutive years, with $1.1 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Finished Goods changed N/A year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Sep 2024, changed N/A, and an annual FY2023 reading of $5.0 million, changed N/A over the prior year.
  • Finished Goods was $1.1 million for Q3 2024 at Zevra Therapeutics, down from $2.1 million in the prior quarter.
  • Across five years, Finished Goods topped out at $5.1 million in Q1 2024 and bottomed at $1.1 million in Q3 2024.